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treatment. IgG levels achieved with Hizentra® were similar to pre-study levels with subcutaneous,
and higher by 17.7% than pre-study levels with intravenous IgG. No serious bacterial infectionswere
reported in the efficacy period. The rate of all infections was 5.18/year/patient, the rates of days
missed from work/school, and days spent in hospital were 8.00/year/patient and 3.48/year/
patient, respectively. Local reactions (rate 0.060/infusion) were mostly mild (87.3%). No serious,
Hizentra®-related adverse events were reported. Individual median infusion durations ranged
between 1.14 and 1.27 h. Hizentra® maintained or improved serum IgG levels without dose
increases and effectively protected patients against infections.
© 2011 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Primary immunodeficiency (PI) disorders with B cell dys-
function, such as common variable immunodeficiency
(CVID), X-linked agammaglobulinemia (XLA) and autosomal
recessive agammaglobulinemia (ARAG), predispose patients
to recurrent infections [1–7]. The mainstay of treatment is
replacement therapy with human polyvalent IgG. Intrave-
nous IgG (IVIG) administration has hitherto been the gold
standard for IgG therapy [8–14]. However, subcutaneous IgG
administration (SCIG) is being increasingly used and, with the
development of more concentrated preparations, has gained
wide acceptance in many countries [15–20].
Hizentra® (IgPro20, recently approved in the US) is a new
20% liquid product with high purity (≥98% IgG) and stability at
25 °C for at least 24 months due to formulationwith 250 mmol/
L L-proline [21]. Owing to the 20% IgG concentration, which is a
technical improvement, and its low viscosity (14.7 ±1.2 mPa∙s),
it can be infused at low infusion volumes and high infusion rates
resulting in potentially shorter infusion times compared to 16%
preparations. TheHizentra®manufacturing process, developed
for the purification of another preparation with similar
formulation, the IVIG IgPro10 (Privigen®), fulfills currently
accepted pathogen safety criteria [22].
The study reported here evaluated for the first time
the efficacy, tolerability, safety, and pharmacokinetics of
Hizentra® in patients with PI at doses equivalent to those
given during previous therapy (IVIG or SCIG). The rationale for
a dose-equivalent switch from previous therapy was based on
the European experience showing that SCIG administered at
doses equivalent to IVIG is sufficient to achieve comparable
IgG trough levels in patients with PI. This approach is reflected
in the European Medicines Agency (EMA) guidelines for
development of SCIG preparations [23]. In contrast, studies
conducted in the US aim at achieving an equivalent IgG
exposure,measuredby the area under the concentration/time
curve (AUC) of serum IgG, as requested by the US Food and
Drug Administration (FDA) [20,24]. The proof of concept of
equivalent IgG doses has been tested in a study of Vivaglobin®,
a 16% SCIG product, which, administered at weekly subcuta-
neous doses equivalent to previous IVIG doses, resulted in IgG
trough levels comparable to those with IVIG [19].
2. Patients and methods
2.1. Patients
Males or females aged 2 to 65 years (16 to 65 years in the United
Kingdom [UK] sites) with CVID or XLA, as defined by Pan-American Group for Immunodeficiency (PAGID) and European
Society for Immunodeficiencies (ESID) [25], or with ARAG were
enrolled in the study. Patients should have received stable IVIG
therapy at regular 3- or 4-week intervals orweekly SCIG therapy
for at least 6 months before study start, at amonthly dose of 0.2
to 0.8 g/kg body weight (bw), with at least 3 documented
serum IgG trough levels of ≥5 g/L. A chest X-ray or computed
tomography (CT) scanobtainedwithin 1 year prior to enrolment
was required. Women of childbearing potential had to have a
negative pregnancy test and use medically approved contra-
ception. Patients participating in thepharmacokinetic substudy
had to be at least 6 years old (at least 16 years old for sites in
the UK).
Patients were excluded if they had never been treatedwith
immunoglobulin replacement therapy, or had an ongoing
serious bacterial infection (SBI) at the time of screening. Other
exclusion criteria were malignancies of the lymphoid system,
allergies or severe reactions to immunoglobulins and other
blood products associated with high anti-IgA concentrations,
hyperprolinemia, hypoalbuminemia, protein-losing enteropa-
thies, significant proteinuria, treatment with steroids (oral or
parenteral, ≥0.15 mg/kg/day of prednisone equivalent) or
other systemic immunosuppressants, and any condition that
was likely to interfere with evaluation of the study medication
or satisfactory conduct of the study. Women who were
pregnant, breast feeding, or planning a pregnancy during the
course of the study were excluded as well.
This study was conducted in accordance with the Interna-
tional Conference on Harmonization (ICH) Good Clinical
Practice (GCP) guidelines, and the Declaration of Helsinki
(version of 1996). The study protocol and all other study-
related documents were reviewed and approved by the
appropriate local Independent Ethics Committees. Written
informed consent was obtained from all patients or patients'
parents or legal guardians.2.2. Study design
This was a prospective, open-label, multicenter, single-arm,
Phase III study with a 12-week wash-in/wash-out period
followed by a 28-week efficacy period (Fig. 1). A pharmaco-
kinetic (PK) substudy was conducted in a subset of patients in
Week 28±1.
Treatmentwas initiatedat a dose equivalent to the previous
IVIG or SCIG dose, given once weekly. Dose adjustments were
permitted during the wash-in/wash-out period if IgG trough
levels were b5 g/L. No further dose adjustments were
permitted during the efficacy period, unless medically
indicated.
Figgure 1 Study design. A schematic presentation of the study design is shown. The hatched area at Week 28 denotes the
pharmacokinetic substudy.
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reduce AEs associated with SCIG infusion was not allowed.
Oral and parenteral steroids were allowed if the average
daily dose was b0.15 mg of prednisone equivalent/kg/day.
Local anesthetics could be used before infusion to reduce the
pain associated with needle insertion if required.
Hizentra® was administered subcutaneously using Crono
PCA-50 or Super-PID infusion pumps (Cane S.R.L., Turin, Italy).
One or more injection sites on the abdomen, thighs, and/or
lateral hip could be used simultaneously and could be changed
every week. The choice of infusion technique varied according
to local practice, with patients already on SCIG treatment
continuing with their established infusion technique. The
initial volume per injection site was limited to 15 mL for
patients switching from IVIG, with the possibility to be
increased up to a maximum of 25 mL after the fourth infusion,
depending on tolerability. Patients on SCIG could continue
using the volume per injection site they had been used to,
provided it did not exceed 25 mL. The total body infusion rate
was not to exceed 25 mL/h during the wash-in/wash-out
period and could be increased up to 35 mL/h during the
efficacy period, depending on tolerability.
Patients were provided with a detailed description of the
infusion technique. Three infusions at the beginning of the
study were supervised and served as training for the patients
or their parents/guardians. Infusions in Weeks 1, 2, 3 (for
patients training in self-administration only), 4, 8, 12, 16,
and 28 had to be performed at the study site under medical
supervision. If a patient/parent/guardian was not able to
perform home therapy after eight supervised infusions, the
patient had to be discontinued from the study.2.3. Efficacy and safety assessments
The primary efficacy endpoint was to compare descriptively
IgG trough levels during 6 consecutive weeks at steady state
(prior to Infusions 12 to 17) with 3 IgG trough levels from the
patient's previous treatment (during the last 3 to 6 months
prior to the study). Trough serum IgG levels were measuredbefore Infusions 1, 4, 8, 12–17, 20 and every fourth infusion
thereafter. The last IgG trough level before the study start
was the IgG trough level measured before the last intrave-
nous infusion for patients previously on IVIG or the IgG trough
level measured before Infusion 1 in this study for patients
previously on SCIG. As the term “IgG trough level” has been
defined to describe the lowest serum IgG level between two
consecutive IVIG infusions, it is not considered appropriate in
SCIG therapy, which maintains stable serum IgG levels,
without “peaks” and “troughs”. Although the term “IgG
trough level” is widely used in subcutaneous IgG therapy
(and, therefore, has been used in the study protocol as such),
we refer to serum IgG concentrations measured before
infusions as “IgG levels” further on in this manuscript.
Secondary efficacy endpoints included rate of clinically
documented serious bacterial infections (SBIs), number of
infection episodes, number of days missed from work/school/
kindergarten/day care or unable to perform normal activities
due to infections (abbreviated further as number of days
missed from work/school), number of days of hospitalization
due to infections, and use of antibiotics for infection
prophylaxis or treatment. Bacterial pneumonia, bacteremia/
septicemia, osteomyelitis/septic arthritis, bacterialmeningitis
and visceral abscess were considered SBIs and were diagnosed
using pre-defined criteria adjusted to both adult and pediatric
patients [26].
The pharmacokinetic endpoints were AUC until the last
measured concentration (AUClast), maximal serum IgG con-
centration (Cmax), and time to reaching Cmax (Tmax). Blood
samples were taken before Infusion 28, 10±5 min prior to end
of infusion, 2±1 h after infusion, and after 1, 2, 3, 4, and
7 days. Serumconcentrations of L-proline and selected specific
antibodies (anti-measles, anti-H. influenzae type B, anti-
tetanus, and anti-S. pneumoniae polysaccharide antibodies)
were determined as previously described [27].
Patients evaluated their satisfaction with Hizentra®
treatment at baseline and at study end (defined as the last
available observation) using the Treatment Satisfaction
Questionnaire for Medication (TSQM) [28]. It includes 14
items, 13 of which are summarized in four domains
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satisfaction’) and 1 was rated as a separate question.
Information about AEs was collected continuously. Patients
documented any findings in their diaries and Investigators
transferred AEs into the Case Report Form (CRF) at visits. Local
reactions at the infusion sitewereexpected to occurdue to the
formation of a drug depot. For the analysis of local reactions,
25 preferred terms of the system organ class (SOC) category
‘General disorders and administration site conditions’ were
combined in the category of local reactions. Local tolerability
was assessed by the patients within 24 to 72 h after infusion
and reviewed by the Investigators during visits.
Vital signs, including blood pressure, heart rate and body
temperature, were evaluated at screening, and before and
after each infusion administered at the study site. Clinical
laboratory parameters were determined at screening, before
Infusions 1, 4, 28, and at the Completion Visit. Direct
Coombs' tests were performed at screening, before Infusions
16 and 28, and, in case of a positive result at Infusion 28, at
the Completion Visit.2.4. Statistical methodology
It was planned to enroll 36 patients, including 12 children
aged b12 years, in approximately 12 centers, to achieve a
sample size of 30 patients including at least 10 children
evaluable for efficacy, tolerability, and safety. Of these
patients, 18 were to be enrolled in the PK substudy in order
to collect PK data of at least 15 patients. This sample size is
consistent with EMA recommendations [29].
Efficacy analyses were carried out on the intent-to-treat
(ITT) population defined as all patients who were treated
with Hizentra® during the efficacy period. Safety analyses
were carried out on the all-treated (AT) population defined
as all patients who were treated with Hizentra® during any
study period. Pharmacokinetic analyses were carried out on
the per-protocol pharmacokinetic (PPK) population that
comprised all patients who had received uniformly repeated
doses of Hizentra® at weekly intervals during at least
12 weeks before Week 28±1 and who provided blood sample
series with not more than 3 missing samples or outliers in the
AUC sampling period.
Descriptive statistics for continuous variables and frequen-
cy distributions for categorical variables were calculated with
the SAS software package (SAS Institute, Cary, NC, USA),
version 9.1.
For primary efficacy analyses, six consecutive steady-
state IgG values were aggregated to the patient's median
value. The same procedure was used for the three most
recent IgG values ≥5 g/L on previous treatment. Median
rather than mean values of the individual IgG levels were
deemed better suited for comparing patients' serum IgG
concentrations because of the high variation of the individual
values.
In addition, all steady-state IgG values obtained in the
efficacy period (before Infusions 12 to 17, 20, 24, 28, 32, 36, and
40) were used for calculation of the aggregated median values
and compared with the IgG values on previous treatment.
The annual rate of SBIs per patient was estimated with
99% upper confidence limit (CL) using a Chi-Square distribu-
tion. The number of infection episodes was estimated with atwo-sided 95% confidence interval (CI). No imputation was
made for patients who discontinued the study.
AUC was obtained by the trapezoidal rule between the
first and last IgG measurements [AUClast], ignoring outliers.
Adverse events were coded using the Medical Dictionary
for Regulatory Activities (MedDRA), version 12.0. Temporally
associated AEs were defined as occurring between the start
of infusion and 72 h after the end of infusion.3. Results
3.1. Patients
Fifty-three Caucasian patients were screened at 15 study
sites in Europe and 51 patients were enrolled in the study.
Forty-six patients completed the wash-in/wash-out period
and 43 patients completed the efficacy period (Fig. 2), of
whom 16 were under the age of 12. Twenty-four patients
were included, and 23 completed the pharmacokinetic
substudy.
The reasons for discontinuation were AEs (6 patients: 3
during the wash-in/wash-out period and 3 during the efficacy
period) and withdrawal of consent (2 patients during the
wash-in/wash-out period). More information about these AEs
is provided below.
Patients' mean age was 21.5 years (Table 1), including 17
children (b12 years) and 5 adolescents (b16 years). The
proportion of patients with XLA was high (n=17) resulting in a
two-fold higher proportion of males. The proportion of males
and females with other diagnoses was similar. There were no
significant differences between the ITT and the PPK
populations with regard to demographic parameters and
thus the PPK population could be considered a representa-
tive sample of all patients. Median duration of disease (since
diagnosis) was 3.4 years for CVID and 7.2 years for XLA. The
patient with ARAG had been diagnosed for 4 years.3.2. Study drug administration
All 46 patients in the ITT population received the intended
12 infusions during the wash-in/wash-out period and 37 pa-
tients (80.4%) received the planned 40 infusions during the
study.
The mean Hizentra® dose per week was 118.7 mg/kg bw
(range 117.0–120.7 mg/kg bw). The mean (SD) of individual
median doseswas 120.0 mg/kg bw (35.72) for the entire study,
with similar values for the wash-in/wash-out period and the
efficacy period. Dose adjustment during thewash-in/wash-out
period was necessary in 7 patients, of whom 2 had a dose
increase of N10%, and 2 had a dose decrease of N10%.
The total body infusion ratemean of medians was 25.3 mL/
h, with 51.7% of infusions performed at 15–25 mL/h and 39.8%
of infusions performed at N25 mL/h. Moreover, 16 patients
(34.8%) had infusions with the maximum infusion rate of
35.0 mL/h using one infusion pump. One patient chose to
infuse with 2 pumps at 70.0 mL/h.
The individual median durations of infusions per week
ranged between 1.14 and 1.27 h, with a mean of medians of
1.27 h (range 0.3–3.3 h).
Figure 2 Patient disposition. The number of patients participating in the study is shown, with an indication of their previous
treatment (IVIG or SCIG).
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3.3.1. Primary efficacy endpoint
Hizentra® treatment resulted in serum IgG levels com-
parable to or higher than those achieved with previous
therapy.Table 1 Demographic and baseline characteristics.
Characteristic ITT population
(N=46)
PPK population
(N=23)
Gender, n (%)
Female 15 (32.6) 8 (34.8)
Male 31 (67.4) 15 (65.2)
Age (years)
Mean (SD) 21.5 (15.60) 20.6 (14.10)
Median (range) 16.5 (3–60) 15.0 (6–49)
Age group, n (%)
2–11 years 17 (37.0) 9 (39.1)
12–15 years 5 (10.9) 3 (13.0)
16–64 years 24 (52.2) 11 (47.8)
Weight (kg)
Mean (SD) 52.1 (24.75) 51.4 (20.92)
Median (range) 55.0 (13–96) 56.0 (20–77)
BMI (kg/m2)
Mean (SD) 20.6 (4.90) 20.3 (3.84)
Median (range) 20.1 (12–32) 20.7 (14–27)
Primary disease
CVID, n (%) 28 (60.9) 11 (47.8)
XLA, n (%) 17 (37.0) 11 (47.8)
ARAG, n (%) 1 (2.2) 1 (4.4)
N = Total number of patients in population; n = Number of
patients; SD = Standard deviation; CVID = Common variable
immunodeficiency; XLA = X-linked agammaglobulinemia; ARAG =
Autosomal recessive agammaglobulinaemia.The pre-study IgG level mean of medians for all patients
was 7.49 g/L (Table 2). The mean IgG level measured before
Infusions 12 to 17 was 8.10 g/L. Thus, as the IgG levels on
Hizentra® were similar to those on previous therapy, the
study objective was met. Nearly identical IgG values were
obtained for the entire efficacy period (Table 2).
Before study start, the mean of individual median IgG
values was higher in patients previously treated with SCIG
(8.43 g/L) compared with patients previously treated with
IVIG (6.78 g/L; Table 3). Thus, IgG levels with Hizentra®
were similar to pre-study levels with SCIG, but were higher
by 17.7% than pre-study levels with IVIG of equivalent dose.3.3.2. Pharmacokinetic parameters
Weekly administration of Hizentra® treatment resulted in
stable IgG levels in children and adults.
As expected for steady-state concentrations, changes in
serum IgG concentrations during one dosing interval (Week
28±1) were small: mean values measured throughout Week
28 ranged between 7.44 and 7.98 g/L (Fig. 3). The mean
maximum serum IgG concentration (Cmax) of 8.26 g/L wasTable 2 Median IgG levels before and during the study.
IgG level in g/L (N=46)
Mean (SD) Median (range)
Pre-study a 7.49 (1.570) 7.02 (5.3–11.7)
Infusions 12 to 17 8.10 (1.443) 7.99 (5.1–12.4)
Infusions 12 to 41 8.10 (1.340) 8.09 (5.2–11.2)
Each patient's values were first aggregated to the median, from
which mean values for the entire population were calculated.
N = Total number of patients in the ITT population; SD = Standard
deviation.
a Data for 2 patients were missing.
Table 3 Comparison of median IgG levels in patient
previously treated with IVIG or SCIG.
IgG level (g/L)
Previous IVIG
(N=27)
Previous SCIG
(N=19)
Pre-study
Mean (SD) 6.78 (1.329) 8.43 (1.375)
Median (range) 6.48 (5.26–11.71) 8.57 (5.36–10.30)
Infusions 12 to 17
Mean (SD) 7.98 (1.569) 8.27 (1.263)
Median (range) 7.72 (6.0–12.4) 8.62 (5.1–10.3)
Infusions 12 to 41
Mean (SD) 7.94 (1.398) 8.33 (1.253)
Median (range) 7.72 (5.9–11.2) 8.73 (5.2–10.2)
Each patient's values were first aggregated to the median and
then median values were analyzed.
IVIG = Intravenous immunoglobulin; SCIG = Subcutaneous
immunoglobulin; N = Number of patients; SD = Standard
deviation.
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53.70 g·day/L.
At the end of this dosing interval (7 days after the Week 28
infusion), the mean serum concentrations of selected specific
antibodieswere higher than those considered protective: anti-
measles antibodies, 1.14 IU/mL (recommended level,
0.24 IU/mL [30]); anti-H. influenzae type B antibodies,
1.92 mg/L (recommended level, 1 mg/L [31]); anti-tetanus
antibodies, 2.31 IU/mL (recommended level, ≥0.1 IU/mL
[32]); except for total anti-S. pneumoniae antibodies,
43.33 mg/L (recommended level N40–70 mg/L depending
on center).
The mean serum L-proline concentration was 259.8 μmol/L
(SD 95.75 μmol/L) prior to the infusion during Week 28. The
mean serum level increased to 370.3±105.79 μmol/L 10 min
prior to the end of the infusion and returned to pre-infusionFigure 3 Mean serum IgG levels during one dosing interval.
Mean and standard errors of the serum IgG concentrations
measured in the pharmacokinetic population (N=23) during
Week 28±1 are shown. Samples were collected as follows: up to
30 min before the start of the infusion (pre-infusion), 10 min
prior to the end of the infusion (10 min), 2 h after the end of the
infusion (2 h), and after 1, 2, 3, 4, and 7 days.level within 2 days after infusion (357.1±99.60 2 h after
infusion, 270.9±84.25 after 1 day, and 252.0±70.44 after
2 days). The normal serum concentration of L-proline is 266±
35 μmol/L [33]. Therefore, no evidence of L-proline accumu-
lation in the circulation was observed.
3.3.3. Secondary efficacy endpoints
Hizentra® was effective in maintaining the rate of
infections to a low level. No SBIs were observed in this
study during the efficacy period (rate 0 events/patient/year;
upper 99% CL 0.192; Table 4). One patient had an SBI of X-ray
proven pneumonia during the wash-in/wash-out period
resulting in a rate of 0.03 events/patient/year for the full
evaluation period in the ITT population (upper 99% CL 0.192).
During the efficacy period, 36 patients (78.3%) experienced
an infection (rate 5.18 infections/patient/year, 95% CI 4.305,
6.171; Table 4). Themost frequent type of infectionwas cough
(16 events), followed by upper respiratory tract infection and
bronchitis (15 events each).
Twenty patients (43.5%) missed work/school on a total of
198 days and 4 patients (8.7%) were hospitalized due to
infections for a total of 86 days (Table 4). These results are
significantly affectedby input froma single patient, a 5-year old
girl who experienced 3 serious AEs (SAEs) resulting in 71 days
missed from school (details are provided in the section Serious
adverse events) and 63 days spent in hospital. Because this
experience differedmarkedly from that of the other patients in
the study, a post-hoc analysis excluding this patient's data was
performed. The results of this analysis showed a decrease in the
number of all infections from 124 to 121, and in the rate of all
infections from 5.18 to 5.16 infections/patient/year. Notably,
the number of missed work/school days and days of hospital-
ization was reduced from 198 to 127 and from 86 to 23,
respectively, with a corresponding reduction in rates from 8.00
to 5.25 days/patient/year and from 3.48 to 0.95 days/patient/
year, respectively (Table 4).
Thirty-two patients (69.6%) were treated with antibiotics
on 1743 days (Table 4). Antibiotics were used for prophylaxis
in 4 patients (8.7%; 297 days), and for the treatment of
adverse events, in 29 patients (63.0%; 873 days). In addition,
7 patients (15.2%) were treated with antibiotics for surgical or
other current conditions on 691 days. Surgical or other current
conditions treated with antibiotics included recurrent or
chronic bronchitis, minor hemoptisis, bronchiectasis, pulmo-
nary emphysema, acne, recurrent urine infection, common
cold, recurrent folliculitis, recurrent or chronic sinusitis and
abnormal lung X-ray. The median duration of antibiotics
treatment was 23 days. In these patients, prolonged use of
antibiotics (N100 days) was required only for prophylaxis or for
the treatment of surgical or other current conditions, except in
the 5-year old patient who was treated for pneumonia with
azithromycin for 116 consecutive days.
In order to investigate the difference in efficacy between
patients previously treated with IVIG or SCIG, a post-hoc
analysis of the efficacy endpoints by previous therapy was
performed (Table 5). The mean age of patients previously
treated with IVIG or SCIG was similar (24.3 years and
23.1 years, respectively), as was the number of children
aged b12 years (8 and 6, respectively). Most endpoints were
lower in patients previously treated with IVIG than in those
previously on SCIG, particularly when excluding the patient
with recurrent pneumonia. Thus, patients previously on IVIG
Table 4 Secondary efficacy endpoints.
Efficacy endpoint a Number (%) of patients a Number of events or days
(annual rate per patient)
SBIs b
[upper 99% CL]
0 0 (0)
[0.192]
All infection episodes b
[95% CI]
36 (78.3) 124 (5.18)
[4.305; 6.171]
35 (76.1) d 121 (5.16) d
[4.285, 6.171] d
Days missed from work/school c 20 (43.5) 198 (8.00)
19 (41.3) d 127 (5.25) d
Days hospitalized due to infection c 4 (8.7) 86 (3.48)
3 (6.5) d 23 (0.95) d
Days with antibiotics for infection
prophylaxis or treatment b
32 (69.6) 1743 (72.75)
31 (67.4) d 1561 (66.62) d
SBI = Serious bacterial infections; CL = Confidence limit; CI = Confidence interval.
a Data from the efficacy period, ITT population (N=46).
b Includes SBIs. The total number of days in the study was 8745.
c The total number of days from patient diaries was 9033.
d Data excluding the patient who suffered from recurrent pneumonias. The total number of days in the study in this analysis was 8552.
The total number of days from patient diaries in this analysis was 8833.
96 S. Jolles et al.had a lower rate of all infections in this study (3.35) than those
previously on SCIG (7.48). Fewer days on antibiotics were
reported in patients previously on IVIG (53.09) compared toTable 5 Comparison of secondary efficacy endpoints in patients
Efficacy endpoint a Previously treated with IVIG
Number (%) of
patients a
Number of
(annual ra
SBIs b
[upper 99% CL]
0 0 (0)
[0.337]
0 [0.351] d
All infection episodes b
[95% CI]
18 (66.7) 47 (3.44)
[2.529, 4.5
17 (65.4) d 44 (3.35) d
[2.435, 4.4
Days missed from work/school c 9 (33.3) 133 (9.44)
8 (30.8) d 62 (4.58) d
Days hospitalized due to infection c 4 (14.8) 86 (6.10)
3 (11.5) d 23 (1.70) d
Days with antibiotics for infection
prophylaxis or treatment b
18 (66.7) 879 (64.36
17 (65.4) d 697 (53.09
Prophylaxis 2 (7.4) 108 (7.91)
2 (7.7) d 108 (8.23)
Treatment of AEs 16 (59.3) 473 (34.63
15 (57.7) d 291 (22.17
Treatment of surgical or other
current conditions
3 (11.1) 405 (29.65
3 (11.54) d 405 (30.85
Prophylaxis and treatment of AEs
(combined)
17 (63.0) 581 (42.54
16 (61.5) d 399 (30.39
SBI = Serious bacterial infections; CL = Confidence limit; CI = Confiden
a Data from the efficacy period, ITT population (N=46).
b Includes SBIs. The total number of days in the study was 4985 for pa
c The total number of days from patient diaries was 5144 for patient
d Data excluding the patient who suffered from recurrent pneumonia
this analysis was 4792 for patients previously on IVIG and 3760 for pat
diaries in this analysis was 4944 for patients previously on IVIG, and 38those on SCIG (83.87), with use for both prophylaxis and
treatment of AEs being lower, while use for other medical
conditions was similar. The same was true for rates of missedpreviously treated with IVIG or SCIG.
(n=27) Previously treated with SCIG (n=19)
events or days
te per patient)
Number (%) of
patients a
Number of events or days
(annual rate per patient)
0 0 (0)
[0.447]
NA NA
18 (94.7) 77 (7.48)
76] [5.899, 9.342]
NA NA
99] d NA
11 (57.9) 65 (6.10)
NA NA
0 (0) 0 (0)
NA NA
) 14 (73.7) 864 (83.87)
) d NA NA
2 (10.5) 189 (18.35)
d NA NA
) 13 (68.4) 400 (38.83)
) d NA NA
) 4 (21.1) 286 (27.76)
) d NA NA
) 13 (68.4) 578 (56.11)
) d NA NA
ce interval.
tients previously on IVIG, and 3760 for patients previously on SCIG.
s previously on IVIG, and 3889 for patients previously on SCIG.
s (previous therapy: IVIG). The total number of days in the study in
ients previously on SCIG. The total number of days from patient
89 for patients previously on SCIG.
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during the last 9 months before this study were 131.5 mg/kg
for previous IVIG therapy (mean of medians; SD 50.00) and
107.0 mg/kg for previous SCIG therapy (mean of medians; SD
28.54), these results suggest a tendency for dose dependence
of the efficacy outcomes. However, the small sample size does
not allow a meaningful statistical comparison of the data.
Patients previously treatedwith IVIG rated SCIG therapywith
Hizentra® as more convenient: the median TSQM domain score
for ‘Convenience’ was 83.3 at study end vs. 55.6 at baseline.
The median change of 33.3 points was statistically significant
(95% CI 22.2, 38.9). In the other TSQM domains, there was slight
or no improvement for patients previously on IVIG. Little or no
change was observed in patients switching from SCIG.
3.4. Safety and tolerability
3.4.1. Local reactions
Local tolerability results showed that patients tolerated
Hizentra® administration well. Local reactions are common
with SCIG administration. In this study, 25 patients (49.0%)
experienced 110 local reactions (rate 0.060 per infusion). The
proportion of patients reporting local reactions decreased over
time: approximately 20% of patients reported local reactions
after the first infusion, but the proportion of patients
experiencing local reactions decreased after the subsequent
infusions, with only b5% of patients reporting local reactions
for 24 of the 29 infusions during the efficacy period. Overall,
1699 of the 1831 infusions (92.8%) were tolerated without any
local reactions (Fig. 4). Most (87.3%) of local reactions were
mild in intensity, 11.8% were moderate, and only 1 (0.9%), an
injection site pruritus, was severe.
Patients evaluated their overall local tolerability as ‘good’
or ‘very good’ for 1767 (96.5%) infusions. Rating of ‘fair’ was
reported for 52 (2.8%) infusions, most of them (65.4%) during
the wash-in/wash-out period; rating of ‘poor’ local tolerability
was reported for 6 (0.3%) infusions only. These results are in
agreementwith the frequency of observed local reactions (only
20% of patients experienced local reactions after the first
infusion). However, contrary to the observed decrease in the
occurrence of local reactions, no clear trend in patients'
tolerability assessments over time was observed, probably dueFigure 4 Local reactions over time. The proportion of patients
experiencing local reactions at each infusion is shown. The
number of patients with available data is given above the lines
marking the infusions for which each number of patients is valid.to the low number of ‘fair’ and ‘poor’ ratings. Two of the 5
patients who rated local tolerability as ‘poor’ after one infusion
had assessed it as ‘good or very good’ after the previous and
subsequent infusions; the other 3 patients discontinued the
study due to AEs, including local reactions in 2 patients with
history of injection site reaction or urticaria.
3.4.2. Overall adverse events
Including local reactions, 50 patients (98.0%) had at least
1 AE, and, overall, 527 AEs occurred during a total of 1831
infusions, resulting in an AE rate of 0.288 per infusion. Apart
from local reactions, the most common AEs were infections
of the respiratory tract and headache (Table 6).
Temporally associated AEs (72 h) occurred in 48 patients
(94.1%). A total of 324 AEs were reported (0.177 AEs/infusion),
themost common being local reactions, followed by headache
and infections of the respiratory tract (Table 6). Thus, the type
and incidence of temporally associated AEs reflected closely
those of all reported AEs.
Overall, 194 AEs experienced by 31 patients (60.8%) were
considered related to Hizentra® administration (0.106 AEs/
infusion). The most common related AEs were headache and
pruritus, with pruritus being also the most frequent
temporally associated AE (Table 7).
Almost all (98.7%) AEs were mild or moderate in intensity.
Seven severe AEs—chest pain, injection site pruritus, appendi-
citis, bronchitis, pneumonia, increased C-reactive protein, and
cough—occurred only once, in 6 patients. Pneumonia and
appendicitiswere SAEs, and chest pain and increasedC-reactive
protein led to discontinuation; more information on these two
AEs is provided in the following sections.
3.4.3. Serious adverse events
Five patients (9.8%) experienced 7 SAEs, none of them
related to the study medication. The SAEs were diarrhea,
pneumonia (2 events), pyrexia, bronchiolitis, appendicitis,
and sciatica. Two of them (pneumonia and appendicitis) were
severe and 1 (diarrhea) was mild in intensity. All but one SAE
resolved without sequelae; the event of sciatica resolved with
sequelae (acute lumboischialgia had resolved; recurrent
ischialgia was ongoing). The patient completed treatment as
planned.
A 5-year old girl with CVID suffered from recurrent
pneumonias and spent markedly more days in hospital and
on antibiotic treatment than the other patients in the study.
She had a complex medical history including recurrent
severe pneumonia flares requiring hospitalization on several
occasions from 2007, and suffered from a number of serious
co-morbidities (atopic dermatitis, varicella, chronic pneu-
monia, mononucleosis syndrome, and recent Enterococcus,
Enterobacter and Candida albicans infections). This was the
patient excluded from the post-hoc analysis performed to
evaluate the efficacy in patients with less severe disease.
She experienced 3 SAEs: 1 event of pyrexia and 2 events of
X-ray proven pneumonia (one of them, occurring in the wash-
in/wash-out period, was classified as an SBI according to the
pre-specified FDA criteria). The first event of pneumonia was
moderate in intensity andwas considered an SBI because chest
X ray/CT scan showed distinctive nodular and new infiltrative
changes of both lungs, despite negative sputum and blood
cultures. Approximately a month later, when the patient was
hospitalized for diagnostic purposes, bronchoalveolar lavage
Table 6 Most common adverse events (experienced by ≥4 patients; AT population).
Adverse event All events Temporally associated (72 h)
No. (%) of patients
(N=51)
No. (rate) a of events
(N=1831)
No. (%) of patients
(N=51)
No. (rate) a of events
(N=1831)
Any adverse event 50 (98.0) 527 (0.288) 48 (94.1) 324 (0.177)
Local reaction b 25 (49.0) 110 (0.060) 24 (47.1) 105 (0.057)
Bronchitis 16 (31.4) 26 (0.014) 7 (13.7) 11 (0.006)
Pyrexia 14 (27.5) 14 (0.008) 7 (13.7) 7 (0.004)
Headache 13 (25.5) 54 (0.029) 9 (17.6) 20 (0.011)
Cough 13 (25.5) 26 (0.014) 7 (13.7) 9 (0.005)
Upper respiratory tract infection 12 (23.5) 17 (0.009) 9 (17.6) 10 (0.005)
Nasopharyngitis 12 (23.5) 20 (0.011) 8 (15.7) 12 (0.007)
Diarrhea 10 (19.6) 16 (0.009) 7 (13.7) 10 (0.005)
Sinusitis 7 (13.7) 11 (0.006) 4 (7.8) 7 (0.004)
Rash 5 (9.8) 5 (0.003) 4 (7.8) 4 (0.002)
Pruritus 4 (7.8) 14 (0.008) 4 (7.8) 13 (0.007)
Respiratory tract infection 4 (7.8) 5 (0.003) 3 (5.9) 3 (0.002)
Oropharyngeal pain 4 (7.8) 12 (0.007) 2 (3.9) 5 (0.003)
Vomiting 4 (7.8) 5 (0.003) 2 (3.9) 2 (0.001)
AT = All treated; N = Total number of patients in population or total number of infusions given in the study.
a Adverse events rates were calculated as proportion of the total number of infusions.
b Local reaction combines the following MedDRA preferred terms: infusion related reaction, infusion site erythema, infusion site
hematoma, infusion site induration, infusion site inflammation, infusion site mass, infusion site edema, infusion site pain, infusion site
pruritus, infusion site rash, infusion site reaction, infusion site swelling, injection site erythema, injection site extravasation, injection
site hematoma, injection site induration, injection site inflammation, injection site nodule, injection site edema, injection site pain,
injection site pruritus, injection site rash, injection site reaction, injection site swelling, and puncture site reaction.
98 S. Jolles et al.was positive for atypical mycobacteria (only in polymerase
chain reaction test). Tests for Mycobacterium tuberculosis
were negative. This SBI resolved after 34 days without
sequelae. Four days after Infusion 14, during the efficacy
period, the patient experienced pyrexia that was reported asTable 7 Most common causally related adverse events (experien
Infusion-related
Adverse event No. (%) of patients
(N=51)
No. (rate)
(N=1831)
Any adverse event 31 (60.8) 194 (0.106
Local reaction b 25 (49.0) 107 (0.058
Headache 6 (11.8) 13 (0.007
Pruritus 4 (7.8) 14 (0.008
Fatigue 3 (5.9) 5 (0.003
Pyrexia 3 (5.9) 3 (0.002
Erythema 2 (3.9) 4 (0.002
Abdominal discomfort 2 (3.9) 3 (0.002
Rash 2 (3.9) 2 (0.001
Bronchitis 2 (3.9) 3 (0.002
Respiratory tract infection 2 (3.9) 3 (0.002
Hypothermia 2 (3.9) 2 (0.001
AT = All treated; N = Total number of patients in population or total n
a Adverse event rates were calculated as proportion of the total num
b Local reaction combines the following MedDRA preferred terms: in
hematoma, infusion site induration, infusion site inflammation, infusio
pruritus, infusion site rash, infusion site reaction, infusion site swelling
site hematoma, injection site induration, injection site inflammation,
injection site pruritus, injection site rash, injection site reaction, injean SAE of moderate intensity; the event resolvedwithin 2 days
without sequelae. Four days after Infusion 22, the patient
experienced pneumonia that was reported as an SAE of severe
intensity. She had fever and cough, and her laboratory tests
were indicative of an ongoing inflammatory process (whiteced by ≥2 patients; AT population).
Infusion-related and temporally
associated(72 h)
a of events No. (%) of patients
(N=51)
No. (rate) a of events
(N=1831)
) 29 (56.9) 165 (0.090)
) 24 (47.1) 102 (0.056)
) 6 (11.8) 9 (0.005)
) 4 (7.8) 13 (0.007)
) 3 (5.9) 4 (0.002)
) 2 (3.9) 2 (0.001)
) 2 (3.9) 4 (0.002)
) 2 (3.9) 3 (0.002)
) 2 (3.9) 2 (0.001)
) 1 (2.0) 1 (0.001)
) 1 (2.0) 1 (0.001)
) 1 (2.0) 1 (0.001)
umber of infusions given in the study.
ber of infusions.
fusion related reaction, infusion site erythema, infusion site
n site mass, infusion site edema, infusion site pain, infusion site
, injection site erythema, injection site extravasation, injection
injection site nodule, injection site edema, injection site pain,
ction site swelling, and puncture site reaction.
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globin 9.7 g/dL; ALT 13.1 U/L). The episodewas ongoing at the
final assessment. Because of the underlying lung disease and
medical history of persistent pneumonia, this event was an
acute exacerbation of the existing pneumonia, and thus not
considered an additional SBI. The patient completed the study
as planned. However, despite major medical intervention and
continuous SCIG treatment, her general condition deteriorated
and she died from respiratory failure two months later.
No deaths occurred during the study.
3.4.4. Adverse events leading to discontinuation
A combination of 14 AEs led to discontinuation of 6 patients
(11.8%). Seven AEs, 4 of them local reactions, in 3 patients
were considered related to Hizentra® administration: injec-
tion site pain, injection site pruritus, injection site reaction (2
events), fatigue, feeling cold, and hypersensitivity. These
resolved without sequelae.
3.4.5. Laboratory tests
Median values and ranges of hematology and serum
chemistry variables did not show any relevant changes over
time. All individual hematology, blood chemistry and urinalysis
values lying outside the normal range were considered by the
investigator not clinically significant.
3.4.6. Direct Coombs' test
There was no evidence of hemolysis during this study, as
evidenced by measurements of hemoglobin and reticulocytes.
One patient, who had a negative direct Coombs' test at
screening, had a positive Coombs' test at the completion visit
after Infusion 9. His hemoglobin values were stable and within
normal range (between 15.0 and 15.8 g/L). The patient
discontinued the study after Infusion 9 due to AEs of injection
site reaction, fatigue, and feeling cold. Four patients had
positive direct Coombs' tests at screening and throughout the
study.4. Discussion
This is the first study of Hizentra® treatment in patients with
PI at doses equivalent to those in previous therapy. The
results showed that Hizentra® is effective in protecting from
serious and non-serious infections and is well tolerated by
patients with PI in all age groups.
The primary objective of this study, achievement of
sustained IgG levels at equivalent doses compared with
previous IVIG or SCIG therapy, was met. IgG levels with
Hizentra® were similar or higher than those on previous
therapy. In particular, results in patients switched fromanother
SCIG to Hizentra® showed that IgG levels were comparable and
thus the bioavailability of different SCIG products was similar.
IgG levels in patients switching from IVIG, on the other hand,
increased by 17.7% with Hizentra® treatment, probably due to
the more frequent, weekly, administration of the monthly
equivalent IVIG dose split into smaller doses. As a result, the
wear-off effect of low IgG levels typical for IVIG administration
could be averted. Thus, switching to Hizentra® treatment from
any previous IgG treatment regimens can be accomplished
without compromising serum IgG levels.In this study, patient evaluation of treatment satisfaction
with Hizentra® was performed for the first time. The results
showed a significant improvement from baseline to study end
in the domain ‘Convenience’ in patients switching from IVIG
and sustained treatment satisfaction in patients switching
from SCIG, suggesting favorable effects on patients' quality
of life.
Hizentra® could be administered conveniently using 2 or 3
sites consecutively, or 2 pumps simultaneously, resulting in
reasonably short infusion times (individual median infusion
durations between 1.14 and 1.27 h). Up to the maximal pump
rate, no decreases in infusion rates due to pump back-
pressure were reported.
Efficacy results in patients previously treated with IVIG or
SCIG were markedly different, yet it was not possible to
establish a clear association with dose due to the small sample
size of the respective subgroups. Rates of infections, antibiotic
use and missed work/school days were lower in patients
previously treated with IVIG compared with those previously
on SCIG, while days in hospital were similar. As IgG doses in this
study were equivalent to previous treatment doses, patients
previously on IVIG were administered generally higher weekly
doses than those previously on SCIG (mean doses 131.5 and
107.0 mg/kg, respectively). These results suggest a moderate
improvement in infection rates with higher dose, but a much
larger sample size would be required to evaluate a possible
dose effect on clinical outcomes.
This study also provides data for comparison with the
efficacy results of the US registration study of Hizentra® [24].
The two studies differ mainly in the initial dose and the
different indicators for dose adjustment: while dose-equiva-
lent switch from IVIG therapy was chosen in this study
according to the clinical practice in Europe, an equivalence
of AUC was aimed at in the US study per FDA guidelines,
resulting in mean doses of 153% the previous IVIG dose during
the efficacy period. The mean weekly doses in the US study
were 176.8–224.3 mg/kg bwcomparedwith 59–243 mg/kg bw
in this study. A direct consequence of the higher doses in theUS
study was the higher mean IgG level achieved: 12.1–12.9 g/L
[24] compared with 7.99–8.25 g/L in this study. In keeping
with the general agreement that higher levels ensure better
protection, several efficacy endpoints were more favorable
with higher IgG levels. For example, while the rate of SBIs was
similar in the two studies, the rate of non-serious infections
was lower in the US study compared with this study (2.76 vs.
5.18 infections/patient/year, respectively) [24]. A similar
relationship was observed for days missed from work/school
(2.06 in the US study vs. 8.00 in this study), days spent in
hospital due to infection (0.2 vs. 3.48, respectively) and use of
antibiotics (48.5 vs. 72.75, respectively). These results might
be biased by the severe disease of the patient with recurrent
pneumonias, as well as the higher number of children in the
European study. The rate of infections in young children is
higher than in adults, and the threshold for children missing
school may be different from that for adults missing work. In
addition, cultural and/or economical differences between
Europe and the US may contribute to the difference in the
number of days missed from work/school and days with
hospitalization.
The impact of almost two-fold higher doses of Hizentra®
administered in the US study on the difference in annualized
infection rates cannot be ruled out. However, several factors
100 S. Jolles et al.may have influenced the observed difference in infection
rates. Only the diagnostic criteria for SBIs were uniformly
defined in the two study protocols. Diagnosis of all other
infections was at investigator's discretion and according to the
national standard of medical practice, including different
diagnostic approaches to infections in various countries.
Therefore, comparing infection rates from different countries
must be performed with caution. In published SCIG studies,
definition and reporting of infections differ substantially due
to differences in the study populations, assessment methods,
statistical analyses, particularly the calculation of infection
rates [34–36]. In this and the US study, any symptom or sign of
infection diagnosed by a participating investigator according
to their national standard of care and reported as an AE, was
counted as an infection, in order to ensure collection of
complete information about any infections patients experi-
enced in the studies. Given the small sample size, the
distribution of individual infection types may vary between
the two studies, contributing to the difference in rates.
The concentrations of specific antibodies were also
different in the two studies. The serum levels of anti-H.
influenzae and anti-tetanus antibodies were 1.5–2-fold higher
in the US study patients (3.32 mg/L and 4.65 IU/mL, respec-
tively, at the end of the weekly dosing interval [27]),
corresponding to the higher dose administered. However, a
disproportionately higher level (compared to the IgG dose
increase) of anti-S. pneumoniae (3–4-fold higher than in the
EU study) was observed in the US study (mean 140.02 mg/L
[27]). It may be possible that the higher level of anti-S.
pneumoniae antibodies could be relevant for the lower
frequency of infections observed in the US study. Patients
entered the two studies with their IgG doses individually
adjusted during previous treatment to keep their infection
rate to the acceptable minimum. Therefore, their doses to a
large extent represented the severity of their PI conditions.
The studies were not designed to evaluate the dose–outcome
relationship on a continuous scale. Due to the relative rarity of
PI conditions, clinical studies of IgG preparations usually have
sample sizes similar to those used in the two Hizentra studies,
which, taken alone, are not powered to answer this question.
Even taking into account the sources of potential bias and
the fact that the studies were not designed to evaluate
outcomes in relation to dose, the results corroborate previous
findings supporting improved outcomes with higher doses of
immunoglobulin. The optimal dose and IgG level in antibody
deficiency are likely to vary between individuals in differing
clinical settings, but the results from this and the US Hizentra®
study underline the importance of high serum IgG concentra-
tions for protection from infections. IgG levels higher than 7 g/
L, which are in the normal range for healthy individuals
[37,38], have been shown to be associated with better clinical
outcomes, if not necessarily with reduced rate of infections
[36,39–41]. A further question about SCIG therapy is whether
subcutaneous doses higher than intravenous doses (resulting
from the AUC matching concept) are necessary and/or
meaningful for switching to SCIG.
This study would suggest that the switch from IVIG to SCIG
therapy does not require an increase in dose tomaintain either
serum IgG levels or a similar clinical outcome with regard to
severe infections. However, regarding the separate question
as to the optimal dose and IgG level, information from this and
the US study supports the increasingly convincing case thathigher IgG levels than those attained with the currently
recommended doses (400–600 mg/kg/month)—with either
IVIG or SCIG therapy—minimize the frequency of serious and
non-serious infections. Further studies are needed to define
whether a higher IgG dose yields benefits in terms of end organ
damage such as bronchiectasis. Standardized and detailed
reporting of clinical outcomes would be necessary to compare
studies and further evaluate the issue.
The efficacy results reported here offer reassurance that PI
patients treated with replacement therapy are well protected
from the burden of recurrent infections to a degree consistent
with sustained health. Thus, similar IgG levels and similar data
for days missed from work/school and days on antibiotics
have been reported with several IVIG preparations [14,41–43].
Our results corroborate also previously reported data for
Vivaglobin®, a 16% SCIG, [16,19,20] suggesting that IVIG and
SCIG preparations show similar efficacy.
Patients tolerated Hizentra® treatment well, with local
reactions mostly mild andmoderate in intensity. Moreover, the
rate of local reactions decreased with ongoing use to an extent
that, for a period of 7 weeks in the second half of the study, no
local reactions were reported. Related systemic AEs such as
headache and fatigue were infrequent and of mild or moderate
intensity.None of the SAEswas related to the studymedication.
Historical infections may have resulted in end organ damage in
the patient with recurrent pneumonias who experienced
several severe AEs. The clinical course in this patient serves
to underline the severity of the potential consequences of PI
and the challenges for the optimal treatment of this group of
patients.
Self-administration was accepted well, as evidenced by the
few discontinuations (8 patients, 15.7%). As many as 21
pediatric patients completed the study, suggesting that
therapywaswell tolerated and fittedwith their daily activities.
In conclusion, following a dose-equivalent switch from
previous IVIG or SCIG therapy, Hizentra® is effective in
maintaining or increasing IgG levels and in protecting PI
patients from infections, and is well tolerated. The short
infusion duration and lack of severe local reactions favor
self-administration.Acknowledgments
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